Fortitude Family Office’s Cymabay Therapeutics CBAY Stock Holding History

Fortitude Family Office’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-48	Closed	-$1.13K	–	1106
2023 Q4	$1.13K	Buy	+48	New	+$855	﹤0.01%	933

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office's CBAY Position: Q1 2024 in Review

Fortitude Family Office sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 48 shares — an estimated $1.13K sold.

Fortitude Family Office first reported a position in CBAY in Q4 2023 and held it in 1 quarter. The position peaked at $1.13K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Fortitude Family Office reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Fortitude Family Office sold 48 Cymabay Therapeutics shares in Q1 2024, an estimated $1.13K.
Fortitude Family Office first reported a position in Cymabay Therapeutics in Q4 2023 and held it in 1 quarter.
Fortitude Family Office's Cymabay Therapeutics position peaked at $1.13K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Fortitude Family Office's 13F filing for Q1 2024, filed 11 Apr 2024.